Abbott touts neuromodulation portfolio’s long-term benefits
Abbott has touted the potential of its neuromodulation portfolio in reducing patient and healthcare burdens associated with chronic pain following…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
CellBxHealth’s new CEO pivots strategy amid financial turnaround efforts
CellBxHealth’s CEO Peter Collins has explained plans to restructure the company following its rebrand from ANGLE in October. The company…
-
Olympus lets 2,000 staff go in endoscopy restructuring initiative
Olympus has initiated a plan to restructure its endoscopy business, following numerous regulatory run-ins and controversy within the company’s leadership…
-
TCT 2025: Elixir Medical’s arterial implant drops coronary events by nearly 50%
Elixir Medical’s coronary implant, DynamX bioadaptor, has been proven to significantly reduce the risk of device-related cardiac events compared with…
-
Organon CEO stands down amid contraceptive sales malpractice probe
Organon CEO Kevin Ali has stepped down from his leading position at the company, following its board’s discovery of sales…
-
J&J spins off orthopaedics business against positive Q3 backdrop
Johnson & Johnson (J&J) has made the latest slimming down move across its company in recent years, saying it plans…
-
RefleXion’s precision radiotherapy offers 100% local tumour control
RefleXion Medical’s SCINTIX biology-guided radiotherapy platform (BgRT) has shined in an observational study involving lung and bone cancer patients. During…
-
ESC 2025: digital outpatient tech reduces heart failure readmission
KiActiv’s digital cardiac rehabilitation programme has significantly reduced heart failure (HF) hospital readmissions while cutting healthcare costs. The 12-week therapy,…
-
Lumaegis secures early funding for unique sterilisation platform
Lumaegis has closed a pre-seed funding round worth $200,000 to advance its RadBox sterilisation device, which uses a new type…
-
ProVerum raises $80m to advance BPH stent system
ProVerum has closed an $80m Series B equity financing round, boosting commercialisation efforts for its ProVee system for benign prostatic…